Acetylcysteine Lysine

CHEMBL6068327 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
309.4 g/mol
LogP
Phase
4

A salt form of acetylcysteine combined with the amino acid lysine, used in some countries as an inhaled or injected mucolytic agent to reduce the thickness and stickiness of mucus in the airways. It works in the same way as acetylcysteine by breaking apart the chemical bonds that make mucus viscous, making it easier to cough up. This formulation may be preferred in certain clinical settings for its improved tolerability profile.

Masse moléculaire

309,3900 g/mol

TPSA

157,00 Ų

Mécanisme d'action

Breaks disulfide bonds in mucus glycoproteins, reducing mucus viscosity and facilitating clearance from the airways.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Breaks disulfide bonds in mucus glycoproteins, reducing mucus viscosity and facilitating clearance from the airways.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N[C@@H](CS)C(=O)O.NCCCC[C@H](N)C(=O)O

InChI

InChI=1S/C6H14N2O2.C5H9NO3S/c7-4-2-1-3-5(8)6(9)10;1-3(7)6-4(2-10)5(8)9/h5H,1-4,7-8H2,(H,9,10);4,10H,2H2,1H3,(H,6,7)(H,8,9)/t5-;4-/m00/s1

Molecular Formula

C11H23N3O5S

HBD / HBA

6 / 8

Liaisons Rotatives

8

Atomes Lourds

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A salt form of acetylcysteine combined with the amino acid lysine, used in some countries as an inhaled or injected mucolytic agent to reduce the thickness and stickiness of mucus in the airways. It works in the same way as acetylcysteine by breaking apart the chemical bonds that make mucus viscous, making it easier to cough up. This formulation may be preferred in certain clinical settings for its improved tolerability profile.

Breaks disulfide bonds in mucus glycoproteins, reducing mucus viscosity and facilitating clearance from the airways.

Yes, Acetylcysteine Lysine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068327. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9883132. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.